Pooja Dua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pooja Dua has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Dong-Ki Lee
Department of Chemistry, Sungkyunkwan University, Suwon, Korea
10 shared publications Soyoun Kim
Department of Medical Biotechnology, Dongguk University, Seoul 100-715, Republic of Korea
9 shared publicationsDong-Ki Lee
Authors' Affiliations: 1Department of Medical Biotechnology, Dongguk University; 2Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul; 3Global Research Laboratory of RNAi Medicine, Department of Chemistry, Sungkyunkwan University, Suwon, Korea; and 4Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Canada
7 shared publications- Soyoun Kim
Dongguk University
7 shared publications Sun Woo Hong
Global Research Laboratory for RNAi Medicine, Department of Chemistry, Sungkyunkwan University, Suwon 440-746, Republic of Korea
4 shared publicationsChiang J. Li
Boston Biomedical Inc. Norwood MA USA
3 shared publications
Latest Publications
- 9 February 2017
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 38 (3) , 324-328
Selection of DNA Aptamers Against Botulinum Neurotoxin E for Development of Fluorescent Aptasensor
Botulinum neurotoxins (BoNTs) produced by Clostridium botulinum are the deadliest toxins known to mankind with a potential of possible bioterrorism agents. Due to the high‐potential harm of these toxins, a sensitive and real‐time monitoring capable detection systems are required for the early stage detection. In this study, a novel sol–gel‐based SELEX was used to isolate single‐stranded nucleic acids (ssDNA) aptamers against purified BoNT type E toxoid (BoNTE) using a chemically synthesized random N40 ssDNA library. The bound aptamer sequences after five rounds were analyzed using next‐generation sequencing and the resulted high‐frequency aptamers were characterized using biolayer interferometry. Among the tested, aptamer BT5.6 showed low nanomolar binding affinity (KD, 53.3 nM) toward BoNTE. As a proof of concept, the aptamer was utilized in a graphene oxide‐based detection platform. In summary, we screened and identified a ssDNA aptamer with high affinity toward BoNTE, which, we believe can be used for development of sensitive detection systems.
- 9 February 2017
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 38 (3) , 324-328
Selection of DNA Aptamers Against Botulinum Neurotoxin E for Development of Fluorescent Aptasensor
Botulinum neurotoxins (BoNTs) produced by Clostridium botulinum are the deadliest toxins known to mankind with a potential of possible bioterrorism agents. Due to the high‐potential harm of these toxins, a sensitive and real‐time monitoring capable detection systems are required for the early stage detection. In this study, a novel sol–gel‐based SELEX was used to isolate single‐stranded nucleic acids (ssDNA) aptamers against purified BoNT type E toxoid (BoNTE) using a chemically synthesized random N40 ssDNA library. The bound aptamer sequences after five rounds were analyzed using next‐generation sequencing and the resulted high‐frequency aptamers were characterized using biolayer interferometry. Among the tested, aptamer BT5.6 showed low nanomolar binding affinity (KD, 53.3 nM) toward BoNTE. As a proof of concept, the aptamer was utilized in a graphene oxide‐based detection platform. In summary, we screened and identified a ssDNA aptamer with high affinity toward BoNTE, which, we believe can be used for development of sensitive detection systems.
- Open Access
- 1 November 2016
- Published by Elsevier in Molecules and Cells
- Vol. 39 (11) , 807-813
Cell-SELEX Based Identification of an RNA Aptamer for Escherichia coli and Its Use in Various Detection Formats
Pooja Dua, Shuo Ren, Sang Wook Lee, Joon-Ki Kim, Hye-su Shin, OK-Chan Jeong, Soyoun Kim, and Dong-Ki Lee. Mol. Cells 2016;39:807-13. https://doi.org/10.14348/molcells.2016.0167
- 1 November 2016
- Published by Elsevier in Molecules and Cells
- Vol. 39 (11) , 807-813
Open AccessCell-SELEX Based Identification of an RNA Aptamer for Escherichia coli and Its Use in Various Detection Formats
Pooja Dua, Shuo Ren, Sang Wook Lee, Joon-Ki Kim, Hye-su Shin, OK-Chan Jeong, Soyoun Kim, and Dong-Ki Lee. Mol. Cells 2016;39:807-13. https://doi.org/10.14348/molcells.2016.0167
- 1 August 2015
- Published by SAGE Publications in Nucleic Acid Therapeutics
- Vol. 25 (4) , 180-187
ALPPL2 Aptamer-Mediated Targeted Delivery of 5-Fluoro-2′-Deoxyuridine to Pancreatic Cancer
Nucleoside analogues are the most promising drugs for the treatment of pancreatic cancer to date. However, their use is often limited due to toxic side effects. Aptamer-mediated targeted delivery of these drugs to cancer cells could maximize their effectiveness and concomitantly minimize the toxic side effects by reducing uptake into normal cells. Previously, we identified a pancreatic cancer-specific, nuclease-resistant RNA aptamer, SQ2, which binds to alkaline phosphatase placental-like 2 (ALPPL2), a putative biomarker for pancreatic cancer. In this study, we demonstrate that the aptamer can be internalized into pancreatic cancer cells and can thus be used for the targeted delivery of therapeutics. Using the aptamer as a ligand, we established that glycophosphatidylinositol-anchored ALPPL2 is internalized by the cells through clathrin-independent and caveolae-dependent or dynamin-mediated cell-type-dependent pathways. Finally, we show that SQ2 can deliver nucleoside drug 5-fluoro-2′-deoxyuridine specifically to ALPPL2-expressing pancreatic cancer cells, inhibiting cell proliferation.
- 1 August 2015
- Published by SAGE Publications in Nucleic Acid Therapeutics
- Vol. 25 (4) , 180-187
ALPPL2 Aptamer-Mediated Targeted Delivery of 5-Fluoro-2′-Deoxyuridine to Pancreatic Cancer
Nucleoside analogues are the most promising drugs for the treatment of pancreatic cancer to date. However, their use is often limited due to toxic side effects. Aptamer-mediated targeted delivery of these drugs to cancer cells could maximize their effectiveness and concomitantly minimize the toxic side effects by reducing uptake into normal cells. Previously, we identified a pancreatic cancer-specific, nuclease-resistant RNA aptamer, SQ2, which binds to alkaline phosphatase placental-like 2 (ALPPL2), a putative biomarker for pancreatic cancer. In this study, we demonstrate that the aptamer can be internalized into pancreatic cancer cells and can thus be used for the targeted delivery of therapeutics. Using the aptamer as a ligand, we established that glycophosphatidylinositol-anchored ALPPL2 is internalized by the cells through clathrin-independent and caveolae-dependent or dynamin-mediated cell-type-dependent pathways. Finally, we show that SQ2 can deliver nucleoside drug 5-fluoro-2′-deoxyuridine specifically to ALPPL2-expressing pancreatic cancer cells, inhibiting cell proliferation.
- 20 February 2014
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 11 (3) , 872-884
Long dsRNA-Mediated RNA Interference and Immunostimulation: A Targeted Delivery Approach Using Polyethyleneimine Based Nano-Carriers
- 20 February 2014
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 11 (3) , 872-884
Long dsRNA-Mediated RNA Interference and Immunostimulation: A Targeted Delivery Approach Using Polyethyleneimine Based Nano-Carriers
- 14 March 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (6) , 1934-1945
Alkaline Phosphatase ALPPL-2 Is a Novel Pancreatic Carcinoma-Associated Protein
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a very low median survival rate. The lack of early sensitive diagnostic markers is one of the main causes of PDAC-associated lethality. Therefore, to identify novel pancreatic cancer biomarkers that can facilitate early diagnosis and also help in the development of effective therapeutics, we developed RNA aptamers targeting pancreatic cancer by Cell-systematic evolution of ligands by exponential enrichment (SELEX) approach. Using a selection strategy that could generate aptamers for 2 pancreatic cancer cell lines in one selection scheme, we identified an aptamer SQ-2 that could recognize pancreatic cancer cells with high specificity. Next, by applying 2 alternative approaches: (i) aptamer-based target pull-down and (ii) genome-wide microarray-based identification of differentially expressed mRNAs in aptamer-positive and -negative cells, we identified alkaline phosphatase placental-like 2 (ALPPL-2), an oncofetal protein, as the target of SQ-2. ALPPL-2 was found to be ectopically expressed in many pancreatic cancer cell lines at both mRNA and protein levels. RNA interference-mediated ALPPL-2 knockdown identified novel tumor-associated functions of this protein in pancreatic cancer cell growth and invasion. In addition, the aptamer-mediated identification of ALPPL-2 on the cell surface and cell secretions of pancreatic cancer cells supports its potential use in the serum- and membrane-based diagnosis of PDAC. Cancer Res; 73(6); 1934–45. ©2012 AACR.
- 14 March 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (6) , 1934-1945
Alkaline Phosphatase ALPPL-2 Is a Novel Pancreatic Carcinoma-Associated Protein
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a very low median survival rate. The lack of early sensitive diagnostic markers is one of the main causes of PDAC-associated lethality. Therefore, to identify novel pancreatic cancer biomarkers that can facilitate early diagnosis and also help in the development of effective therapeutics, we developed RNA aptamers targeting pancreatic cancer by Cell-systematic evolution of ligands by exponential enrichment (SELEX) approach. Using a selection strategy that could generate aptamers for 2 pancreatic cancer cell lines in one selection scheme, we identified an aptamer SQ-2 that could recognize pancreatic cancer cells with high specificity. Next, by applying 2 alternative approaches: (i) aptamer-based target pull-down and (ii) genome-wide microarray-based identification of differentially expressed mRNAs in aptamer-positive and -negative cells, we identified alkaline phosphatase placental-like 2 (ALPPL-2), an oncofetal protein, as the target of SQ-2. ALPPL-2 was found to be ectopically expressed in many pancreatic cancer cell lines at both mRNA and protein levels. RNA interference-mediated ALPPL-2 knockdown identified novel tumor-associated functions of this protein in pancreatic cancer cell growth and invasion. In addition, the aptamer-mediated identification of ALPPL-2 on the cell surface and cell secretions of pancreatic cancer cells supports its potential use in the serum- and membrane-based diagnosis of PDAC. Cancer Res; 73(6); 1934–45. ©2012 AACR.
- 29 August 2012
- Published by Springer Nature
- Vol. 942, 135-152
The Design, Preparation, and Evaluation of Asymmetric Small Interfering RNA for Specific Gene Silencing in Mammalian Cells
RNA interference (RNAi) is a highly efficient endogenous gene silencing mechanism mediated by short double-stranded RNAs termed small interfering RNAs (siRNAs). The current standard siRNA structure, which is used by most researchers to trigger sequence-specific target gene silencing, consists of a double strand region of 19 bp with 2 nt 3′-overhangs at both ends. However, in addition to the desired target gene silencing, this conventional siRNA structure also exhibits several unintended effects that constitute obstacles to the use of siRNA in gene function studies and therapeutics development. Here, we provide protocols for designing and preparing an alternative structure for RNAi trigger, termed asymmetric shorter-duplex RNA (asiRNA). The asiRNA structure has a duplex region shorter than 19 bp and has an asymmetric 3′-overhang structure. Importantly, the asiRNA structure not only triggers efficient target gene silencing comparable to that of the 19 bp standard siRNA structure but also significantly reduces nonspecific effects triggered by 19 bp siRNAs such as sense-strand-mediated off-target silencing and the saturation of RNAi machinery. Procedures are described for verifying that asiRNA activates gene silencing through an Ago2-dependent pathway and for assessing the miRNA pathway competition potency and specific and nonspecific silencing abilities of asiRNAs. We propose that asiRNA, an improved RNAi trigger that can overcome the nonspecific effects evoked by standard siRNA structures, can be developed as a precise and effective tool for both functional genomics and therapeutic applications.
- 29 August 2012
- Published by Springer Nature
- Vol. 942, 135-152
The Design, Preparation, and Evaluation of Asymmetric Small Interfering RNA for Specific Gene Silencing in Mammalian Cells
RNA interference (RNAi) is a highly efficient endogenous gene silencing mechanism mediated by short double-stranded RNAs termed small interfering RNAs (siRNAs). The current standard siRNA structure, which is used by most researchers to trigger sequence-specific target gene silencing, consists of a double strand region of 19 bp with 2 nt 3′-overhangs at both ends. However, in addition to the desired target gene silencing, this conventional siRNA structure also exhibits several unintended effects that constitute obstacles to the use of siRNA in gene function studies and therapeutics development. Here, we provide protocols for designing and preparing an alternative structure for RNAi trigger, termed asymmetric shorter-duplex RNA (asiRNA). The asiRNA structure has a duplex region shorter than 19 bp and has an asymmetric 3′-overhang structure. Importantly, the asiRNA structure not only triggers efficient target gene silencing comparable to that of the 19 bp standard siRNA structure but also significantly reduces nonspecific effects triggered by 19 bp siRNAs such as sense-strand-mediated off-target silencing and the saturation of RNAi machinery. Procedures are described for verifying that asiRNA activates gene silencing through an Ago2-dependent pathway and for assessing the miRNA pathway competition potency and specific and nonspecific silencing abilities of asiRNAs. We propose that asiRNA, an improved RNAi trigger that can overcome the nonspecific effects evoked by standard siRNA structures, can be developed as a precise and effective tool for both functional genomics and therapeutic applications.
- 30 July 2012
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 6 (8) , 7151-7161
Dual Functions of Highly Potent Graphene Derivative–Poly-l-Lysine Composites To Inhibit Bacteria and Support Human Cells
Dual-function poly(l-lysine) (PLL) composites that function as antibacterial agents and promote the growth of human cell culture have been sought by researchers for a long period. In this paper, we report the preparation of new graphene derivative–PLL composites via electrostatic interactions and covalent bonding between graphene derivatives and PLL. The resulting composites were characterized by infrared spectroscopy, scanning electron microscopy, and X-ray photoelectron spectroscopy. The novel dual function of PLL composites, specifically antibacterial activity and biocompatibility with human cells [human adipose-derived stem cells and non-small-cell lung carcinoma cells (A549)], was carefully investigated. Graphene–DS–PLL composites composed of 4-carboxylic acid benzene diazonium salt (DS) generated more anionic carboxylic acid groups to bind to cationic PLLs, forming the most potent antibacterial agent among PLL and PLL composites with high biocompatibility with human cell culture. This dual functionality can be used to inhibit bacterial growth while enhancing human cell growth.
- 30 July 2012
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 6 (8) , 7151-7161
Dual Functions of Highly Potent Graphene Derivative–Poly-l-Lysine Composites To Inhibit Bacteria and Support Human Cells
Dual-function poly(l-lysine) (PLL) composites that function as antibacterial agents and promote the growth of human cell culture have been sought by researchers for a long period. In this paper, we report the preparation of new graphene derivative–PLL composites via electrostatic interactions and covalent bonding between graphene derivatives and PLL. The resulting composites were characterized by infrared spectroscopy, scanning electron microscopy, and X-ray photoelectron spectroscopy. The novel dual function of PLL composites, specifically antibacterial activity and biocompatibility with human cells [human adipose-derived stem cells and non-small-cell lung carcinoma cells (A549)], was carefully investigated. Graphene–DS–PLL composites composed of 4-carboxylic acid benzene diazonium salt (DS) generated more anionic carboxylic acid groups to bind to cationic PLLs, forming the most potent antibacterial agent among PLL and PLL composites with high biocompatibility with human cell culture. This dual functionality can be used to inhibit bacterial growth while enhancing human cell growth.
- 20 February 2012
- Published by Wiley in The Journal of Gene Medicine
- Vol. 14 (2) , 138-146
Enhanced intracellular delivery and multi‐target gene silencing triggered by tripodal RNA structures
Background: The development of gene interfering RNA (iRNA) molecules such as small interfering RNAs (siRNAs) and antagomirs provides promising therapeutic modalities for targeting specific mRNAs and microRNAs (miRNAs) involved in disease mechanisms. Therapeutic iRNA strategy against cancer or hypermutable viruses prefers targeting multiple genes simultaneously to achieve synergistic inhibition and to prevent resistance.Methods: In the present study, we report chemically synthesized, multi‐target gene interfering RNA structures based upon branched, tripodal interfering RNAs (termed T‐tiRNAs).Results: The T‐tiRNAs could simultaneously inhibit up to three different mRNAs or miRNAs by harboring three siRNA or antagomir units. Moreover, when complexed with cationic delivery vehicles, T‐tiRNAs showed enhanced gene interfering activity over conventional siRNAs or antagomirs as a result of increased intracellular delivery.Conclusions: The data obtained in the present study provide an example of synthetic multi‐functional RNA structures that enable multiple gene interference in mammalian cells, which could become powerful tools for an efficient combinatorial iRNA strategy. Copyright © 2012 John Wiley & Sons, Ltd.
- 20 February 2012
- Published by Wiley in The Journal of Gene Medicine
- Vol. 14 (2) , 138-146
Enhanced intracellular delivery and multi‐target gene silencing triggered by tripodal RNA structures
Background: The development of gene interfering RNA (iRNA) molecules such as small interfering RNAs (siRNAs) and antagomirs provides promising therapeutic modalities for targeting specific mRNAs and microRNAs (miRNAs) involved in disease mechanisms. Therapeutic iRNA strategy against cancer or hypermutable viruses prefers targeting multiple genes simultaneously to achieve synergistic inhibition and to prevent resistance.Methods: In the present study, we report chemically synthesized, multi‐target gene interfering RNA structures based upon branched, tripodal interfering RNAs (termed T‐tiRNAs).Results: The T‐tiRNAs could simultaneously inhibit up to three different mRNAs or miRNAs by harboring three siRNA or antagomir units. Moreover, when complexed with cationic delivery vehicles, T‐tiRNAs showed enhanced gene interfering activity over conventional siRNAs or antagomirs as a result of increased intracellular delivery.Conclusions: The data obtained in the present study provide an example of synthetic multi‐functional RNA structures that enable multiple gene interference in mammalian cells, which could become powerful tools for an efficient combinatorial iRNA strategy. Copyright © 2012 John Wiley & Sons, Ltd.
- Open Access
- 1 September 2011
- Published by Elsevier in Molecular Therapy
- Vol. 19 (9) , 1676-1687
Modified siRNA Structure With a Single Nucleotide Bulge Overcomes Conventional siRNA-mediated Off-target Silencing
- 1 September 2011
- Published by Elsevier in Molecular Therapy
- Vol. 19 (9) , 1676-1687
Open AccessModified siRNA Structure With a Single Nucleotide Bulge Overcomes Conventional siRNA-mediated Off-target Silencing
- 20 June 2011
- Published by Korean Chemical Society in Bulletin of the Korean Chemical Society
- Vol. 32 (6) , 2051-2057
Evaluation of Toxicity and Gene Expression Changes Triggered by Oxide Nanoparticles
- 20 June 2011
- Published by Korean Chemical Society in Bulletin of the Korean Chemical Society
- Vol. 32 (6) , 2051-2057
Evaluation of Toxicity and Gene Expression Changes Triggered by Oxide Nanoparticles